Psychiatrist Opportunity – No Call, Nights, or Weekends!

TMS NeuroHealth Texas PLLC (a division of Greenbrook TMS NeuroHealth Centers Services, LLC) is seeking Board-Certified or Board-Eligible Psychiatrists to provide on-site TMS therapy and help expand our Spravato program in Pflugerville, Texas.

Join a national leader in innovative care for treatment-resistant depression, OCD, and other mental health conditions.

Why Join Greenbrook?

• Innovative Care: Use FDA-cleared TMS and Spravato® treatments
• No Call, Weekends, or Evenings
• Flexible Scheduling to fit your lifestyle
• Competitive Pay + Additional Income Opportunity
• TMS Certification & Training Provided
• Supportive Team Environment with clinical leadership and management backing
• Make a Real Difference: Help patients who haven't responded to traditional therapies

About Greenbrook

With 95+ locations across the U.S., Greenbrook has administered over 1.3 million treatments to 40,000+ patients. We're transforming lives through advanced, non-invasive treatments that restore hope and healing.

Over 16 million Americans struggle with depression. At Greenbrook, we’re changing how it’s treated—one patient at a time.

• Our Mission: Why We Do It
• Patient Stories: How We Help
• Provider Info: Learn More

Requirements

• MD/DO with active U.S. Board Certification or Eligibility in Psychiatry
• Must be authorized to work in the U.S.

Commitment to Diversity

Greenbrook is an Equal Opportunity Employer. We are committed to a workplace free of discrimination and inclusive of all backgrounds, abilities, and experiences—including individuals with disabilities and protected veterans.

Neuronetics, Inc. is a leading mental healthcare company, now encompassing Greenbrook TMS as a subsidiary. This strategic acquisition unites Neuronetics' innovative NeuroStar® Advanced Therapy (TMS) technology with Greenbrook's extensive network of over 95 U.S. treatment centers. The combined company provides FDA-cleared NeuroStar® TMS and Spravato® treatments for major depressive disorder (MDD) and treatment-resistant depression. With a strengthened nationwide footprint, Neuronetics is dedicated to significantly expanding patient access to these crucial therapies, integrating advanced technology with established clinical expertise to improve patient outcomes and drive growth within the mental health sector.